Thus, for example, prostate, breast, and melanoma cancer cells present LIMK1 overexpression [29, 30], whereas LIMK2 was found to be overexpressed in several gene arrays testing changes in gene expression in several cancer types such as ovarian carcinoma, head and neck cancer, and several pancreatic cancer cell lines (CanSER database), and is a predictive marker of drug resistance [31]. This evidence concerns the gene LIMK2 and familial pancreatic carcinoma.